GUILDFORD, UK, and BURLINGTON, Mass.—Ablynx has recently deployed IDBS' E-WorkBook Suite in order to manage data related to the discovery and development of Nanobodies, a new class of antibody-derived therapeutic proteins for treatment in major disease areas such as oncology, pulmonary disease, inflammation and thrombosis. The E-WorkBook Suite is a data management solution that provides the ability to maximize R&D data, simplify workflow and protect intellectual property assets, and enable scientists to analyze and share data in a secure environment. Dominique Vlieghe, senior bioinformatician at Ablynx, says that "in E-WorkBook, we believe we have found a complete solution that will support both rigid and flexible workflows. E-WorkBook contains native functionality suited to our requirements." Neil Kipling, IDBS' founder and CEO, says Ablynx's selection of the data management suite "is testament to E-WorkBook's position as the leading biologics solution."